跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,956 条关于
“Pentixapharm Holding AG”
全部
3,956
临床试验
1,800
药物
441
机构
538
资讯
1,177
去年
NCI and NIDDK Initiate Phase II Trial of PentixaFor for Adrenal Tumor Subtyping
6个月前
Pentixapharm Receives FDA Approval for CXCR4-Targeted Radiotheranostic Program in Blood Cancers
去年
Phase I/II Trial of Lu177-PentixaTher Initiated for Relapsed/Refractory AML and ALL
去年
Phase I/II Trial of Lu177-PentixaTher Initiated for Relapsed/Refractory AML and ALL
去年
Pentixapharm Pivots Clinical Strategy to Focus on CXCR4-Targeted Theranostic Oncology Platform
去年
Pentixapharm's Lu177-PentixaTher Enters Phase I/II Trial for AML and ALL
9个月前
Pentixapharm Receives FDA Guidance for Phase 3 PANDA Study of 68Ga-PentixaFor in Primary Aldosteronism
11个月前
Pentixapharm's CXCR4-Targeted Radiopharmaceuticals Show Promise in Primary Aldosteronism and Bladder Cancer
4个月前
Pentixapharm Submits IND to FDA for Phase 3 PANDA Trial of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
去年
Fabhalta Demonstrates Sustained Efficacy in Phase III C3 Glomerulopathy Trial
第 1 页,共 118 页
上一页
下一页